FLUDEOXYGLUCOSE F18

Post-LOE

fludeoxyglucose f-18

Biomed
ANDAINTRAVENOUSINJECTABLE
Approved
May 2015
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Company
B
Biomed
Australia - Sydney
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers